Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study to Examine Grape Seed Extract as an Anti-Oligomerization Agent in Alzheimer's Disease (AD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* NINCDS/ADRDA criteria for probable AD~* MMSE between 12-26~* Treatment with a cholinesterase inhibitor or an NMDA (N-methyl-D-asparate) antagonist with stable dose for at least 12 weeks~* Home monitoring available for supervision of medications~* Caregiver available to accompany patient to all visits and willing to participate in study as informant~* Fluent in English or Spanish~* Medical stability for this study as confirmed by review of records, internist's physical exam, neurological exam, and laboratory tests~* Stable doses of non-excluded medication~* No evidence of hepatic insufficiency~* Able to swallow oral medications~* Ability to participate in the informed consent process~Exclusion Criteria:~* History of hypotension or unstable hypertension~* Active hepatic or renal disease~* Use of another investigational drug within the past two months~* History of clinically significant stroke~* History of seizure or head trauma with disturbance of consciousness within the past two years~* Major mental illness including psychotic disorders, bipolar disorder, or major depressive episode that is not in remission for less than 12 months~* Women of child-bearing age unless using effective birth control or at least one year post-menopausal or surgically menopausal~* Any ferrous or metallic materials which are contraindicated for MRI~Medication Exclusions~* Current use of drugs with significant anticholinergic or antihistaminic properties

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Meganatural-Az Grapeseed Extract (Type: ACTIVE_COMPARATOR): Meganatural-Az® doses: 30mg / day for 2 weeks; 4 weeks of 600 mg/day, 4 weeks 1000mg / day
- Placebo (Type: PLACEBO_COMPARATOR): Subjects receive capsules identical in appearance to the active agent with the same incremental schedule

Based on this trial design, predict the completion outcome and termination type (if applicable).